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Abstract
Background: Overexpression of the ERBB2 kinase is observed in about one-third of breast cancer patients and the dual
ERBB1/ERBB2 kinase inhibitor lapatinib was recently approved for the treatment of advanced ERBB2-positive breast cancer.
Mutations in the ERBB2 receptor have recently been reported in breast cancer at diagnosis and also in gastric, colorectal and
lung cancer. These mutations may have an impact on the clinical responses achieved with lapatinib in breast cancer and
may also have a potential impact on the use of lapatinib in other solid cancers. However, the sensitivity of lapatinib towards
clinically observed ERBB2 mutations is not known.
Methodology/Principal Findings: We cloned a panel of 8 clinically observed ERBB2 mutations, established stable cell lines
and characterized their sensitivity towards lapatinib and alternative ERBB2 inhibitors. Both lapatinib-sensitive and lapatinib-
resistant ERBB2 mutations were observed. Interestingly, we were able to generate lapatinib resistance mutations in wt-
ERBB2 cells incubated with lapatinib for prolonged periods of time. This indicates that these resistance mutations may also
cause secondary resistance in lapatinib-treated patients. Lapatinib-resistant ERBB2 mutations were found to be highly
resistant towards AEE788 treatment but remained sensitive towards the dual irreversible inhibitors CL-387785 and WZ-4002.
Conclusions/Significance: Patients harbouring certain ERBB2 kinase domain mutations at diagnosis may not benefit from
lapatinib treatment. Moreover, secondary lapatinib resistance may develop due to kinase domain mutations. Irreversible
ERBB2 inhibitors may offer alternative treatment options for breast cancer and other solid tumor patients harbouring
lapatinib resistance mutations. In addition, these inhibitors may be of interest in the scenario of secondary lapatinib
resistance.
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Introduction
ERBB2 amplification or overexpression was reported in 30% of
breast cancers and is correlated with poor prognosis, increased
metastatic potential and resistance to apoptosis[1]. More recently,
mutations in the ERBB2 kinase domain were also reported in
various solid cancers[2–7]. Previous studies have shown that a
solid tumor entity can be uniformly addicted to a specific
oncogenic kinase, and the presence of activating mutations within
a specific kinase determines response to therapeutic kinase
inhibition. For example, activating ErbB1 mutations determine
the response to EGFR kinase inhibitors such as gefitinib and
erlotinib[8]. Moreover, it has been shown that the specific type of
mutation within the kinase domain of an oncoprotein determines
differential responses towards different kinase inhibitors[9,10].
Thus, it is important to biochemically characterize individual
mutations and to devise experimental cellular systems to test the
efficacy of inhibitors against them. A comprehensive study to
establish drug sensitivity profiles for mutations reported in the
clinic allows selection of the appropriate treatment strategy in
patients. To this end, we aimed to establish drug sensitivity profiles
of ERBB2 kinase domain mutants against ERBB2 inhibitors.
Lapatinib is a dual inhibitor of EGFR and ERBB2 kinases. In
the present study the efficacy of lapatinib against ERBB2 variants
was studied. Moreover, a cell based screening strategy was
employed to identify lapatinib resistant ERBB2 kinase domain
mutations. The effect of another reversible dual EGFR/ERBB2
inhibitor AEE 788, was tested against ERBB2 mutants. Together,
comprehensive drug sensitivity profiles for various ERBB2
mutations that were reported in several cancers were established
along with the identification of lapatinib resistant mutations.
Furthermore, irreversible ERBB2 inhibitors were identified which
potentially can overcome lapatinib resistance.
Results and Discussion
Identification of lapatinib resistant ERBB2 kinase domain
mutations
It has been demonstrated that the drug sensitivity of different
mutations varies against selective inhibitors. Thus, we aimed to
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8test the efficacy of reversible ERBB2 inhibitors lapatinib and
AEE788 against a panel of ERBB2 kinase domain mutations that
were reported in various solid cancers (Table 1). Analogous
mutations in EGFR were reported for most of the ERBB2
mutations analyzed in this study (Table S1), suggesting that these
mutations are not passenger mutations but functionally important.
Additionally, a gatekeeper mutation T798M was cloned for
analysis. ERBB2-T798M is analogous to EGFR-T790M that was
shown to cause resistance towards EGFR inhibitors[10,11]. The
locations of the kinase domain mutants investigated in this study
are depicted in Figure 1. Four mutations are located in the N-lobe
of the kinase. L755 is located at a loop adjacent to helix C, V773
and V777 are at or near the C-terminal portion of helix C, and
T798 is at the gatekeeper position in the ATP binding site
(Figure 1A and B). Of the remainder, N857 is located in helix D,
T862A forms the base of the ATP binding site, and H878 is in the
activation loop.
All the mutations analyzed retained autokinase activity and
activated downstream signaling pathways when expressed in
HEK293 cells (Figure 2A). Moreover mutations L755S, L755P,
V777L, T798M and T862A displayed enhanced activation of
JNK/SAPK and to a lesser extent of ERK1/2 compared to wt-
ERBB2 (Figure 2A). Enhanced autophosphorylation as well as
activation of downstream signaling molecules was also observed
upon stimulation with either EGF or heregulin of serum starved
HEK293 cells expressing ERBB2 in combination with EGFR or
ERBB3 (Figure 2B) indicating that the mutations did not interfere
with ligand-induced heterodimerization of the ERBB2 mutants
Table 1. Summary of ERBB2 mutants analyzed along with the IC50 values against reversible inhibitors lapatinib and AEE788.
ERBB2
mutation Exon Functional region Cancer type Lapatinib AEE788 Reference
WT NA NA Breast cancer 30 257 NA
L755S 19 ATP binding region Breast and gastric cancer .2000 897 4
L755P 19 ATP binding region NSCLC 1545 1216 2,3
V773A 20 ATP binding region SCCHN 146 200 6
V777L 20 ATP binding region Gastric, colon and lung 27 215 3,4
T798M 20 Gate keeper residue NA 1433 .2000 NA
N857S 21 Activation loop Ovarian cancer 75 246 2
T862A 21 Activation loop Primary gastric cancer 125 191 7
H878Y 21 Activation loop Hepatocellular carcinoma 14 168 5
ERBB2 kinase domain mutations that were reported in solid cancers were shown along with their structural position and IC50 values against lapatinib and AEE 788. IC50
values were calculated based on Figures 1C and 1D.
doi:10.1371/journal.pone.0026760.t001
Figure 1. Schematic representation of ERBB2 mutations analyzed. (A and B) The side chains of mutants considered in this study are plotted
(red sticks) together with a schematic representation of the protein fold using the crystal structure of EGFR kinase in complex with erlotinib (green
sticks). B) is a view roughly orthogonal to A) and shows additional inhibitors gefitinib (yellow sticks) and lapatinib (blue sticks) superimposed at the
ATP binding site.
doi:10.1371/journal.pone.0026760.g001
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transformed mouse mammary epithelial cell line) stably expressing
wt- or mutant-ERBB2 formed distinct colonies in six-well cell
culture plates (Figure S1) as well as in soft agar (Figure 3A).
Hereby, ERBB2-L755S, ERBB2-L755P, ERBB2-V777L and
ERBB2-T862A formed more colonies compared to wt- ERBB2
(Figure 3B) indicating an enhanced transforming potential.
Interestingly, late passage NMuMg cells stably expressing
ERBB2-L755S, ERBB2-L755P, ERBB2-V777L, ERBB2-
T798M, ERBB2-T862A and ERBB2-H878Y also formed colonies
in liquid culture in contrast to wt-ERBB2 also supporting
enhanced transforming potential of these ERBB2 mutants (Figure
S2). Similar observations were made in a recent report with
NIH3T3 cells expressing ERBB2-L755S[12].
We next aimed to establish additional ERBB2 mutant
expressing cell lines, which completely depend on the overex-
pressed ERBB2 for their survival. This allows to study their
sensitivity towards different kinase inhibitors in a convenient way.
Thus, ERBB2 mutations were cloned into the MiGR1 (MSCV-
eGFP) vector and stable expressing Ba/F3 cell lines were
established. Both wild type ERBB2 and ERBB2 mutants conferred
Ba/F3 cells to cytokine independence (data not shown). We then
tested the inhibitory effects of lapatinib (Figure S3) on these stable
Ba/F3 cell lines expressing ERBB2 mutants. Cell proliferation
analysis showed that the ERBB2-H878Y mutant had the highest
sensitivity against lapatinib among all mutations tested with a
cellular IC50 value nearly half to that of wild type ERBB2
(Figure 4A and Table 1). A similar sensitizing effect of ERBB2-
H878Y towards lapatinib was shown recently in CHO cells
measuring autophosphorylation of the receptor [13]. Thus,
ERBB2-H878Y, which was reported in 11% of hepatoma
patients[5], can be considered as a lapatinib-sensitizing mutation
similar to EGFR-L858R that was reported as gefitinib-sensitizing
mutation in NSCLC[8]. Another mutation, ERBB2-V777L also
remained sensitive to lapatinib with a cellular IC50 value similar to
that of wild type ERBB2 (Figure 4A and Table 1). However, all
remaining mutations showed a shift towards significant higher
cellular IC50 values compared to the wild type receptor (Figure 4A
and Table 1). Since levels of up to 1 mM of lapatinib may be
achieved in patients, ERBB2-V773A, ERBB2-T862A and
ERBB2-N857S (IC90 approximately 0.5 mM) mutations might
respond to higher doses of lapatinib. In contrast, ERBB2-L755S
Figure 2. Biochemical analysis of ERBB2 mutants. (A) HEK293 cells were transfected with either wild type (WT) or mutant ERBB2 for 36 hours
and analyzed for autophosphorylation and activation of downstream signaling molecules. Untransfected (UT) cells were taken as control for ERBB2
expression. (B) HEK293 cells were transfected with a combination of ERBB2 (WT or mutant) and EGFR (left two panels) or ERBB3 constructs (right two
panels) for 36 hours followed by serum starvation for 12 hours. Cells were then stimulated with either EGF (left two panels) or heregulin (right two
panlels) for 5 minutes and analyzed for the activation of ERBB2 as well as downstream signaling pathways by western blotting. Untransfected (UT)
cells were used as control.
doi:10.1371/journal.pone.0026760.g002
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T798M (IC50.1 mM) caused strong lapatinib resistance
(Figure 4A and Table 1). These results indicate that the amino
acids L755 and T798 in ERBB2 are critical residues determining
lapatinib sensitivity and those patients with these mutations may
not respond to lapatinib treatment. In summary, based on
lapatinib sensitivity, ERBB2 kinase domain mutations can be
classified into three groups: (1) lapatinib-sensitizing (IC50#30 nM)
– ERBB2-H878Y & ERBB2-V777L; (2) lapatinib-sensitive (IC50
value between 30 nM and 1 mM) – ERBB2-V773A, ERBB2-
N857S & ERBB2-T862A and (3) lapatinib-resistant (IC50.1 mM)
– ERBB2-L755S, ERBB2-L755P & ERBB2-T798M.
Breast cancer patients with wild type ERBB2 kinase may develop
secondary resistance to lapatinib due to kinase domain mutations
similar to secondary drug resistance reported in NSCLC or CML
patients treated with kinase inhibitors. To test the hypothesis
whether ERBB2 resistance mutations identified above can lead to
secondary drug resistance in vitro we performed a classical drug
resistancescreenasdescribed beforeusing 2 mM oflapatinib(Figure
S4). Indeed we were able to recover secondary resistance mutations
in this screen (ERBB2-L755S and ERBB2-T862A) indicating the
possible emergence of resistance mutations in WT-ERBB2 patients
treated with lapatinib (Figure S4). Interestingly, ERBB2-L755S was
also reported recently in an in vitro lapatinib-resistance screen
performed at concentrations 0.4 mM, 0.6 mM, 0.8 mMa n d
1.2 mM[12]. Thus, comprehensive sequence analysis of secondary
lapatinib resistant patients will be necessary in the future to
determine whether this is a clinically important resistance
mechanism in breast cancer patients as already demonstrated in
CML or NSCLC patients.
We next tested whether ERBB2 kinase domain mutations
exhibit differential sensitivity towards an alternative reversible
ERBB2 inhibitor, AEE788 (Figure S3). Interestingly, overall the
efficacy of this inhibitor was not altered by most mutations except
ERBB2-L755S, ERBB2-L755P and ERBB2-T798M (Figure 4B
and Table 1). While ERBB2-L755S and ERBB2-L755P mutants
remained sensitive to AEE788 at very high concentrations (IC90
below 2 mM), the gatekeeper ERBB2-T798M mutation is totally
resistant (IC50.2 mM) to AEE788 treatment (Figure 4B). Thus,
lapatinib and AEE788 indeed display differential sensitivities to
most ERBB2 mutants while ERBB2-L755S, ERBB2-L755P and
ERBB2-T798M showed cross-resistance to both inhibitors.
Figure 3. Anchorage-independent growth of ERBB2 mutants. (A) NMuMg cells stably expressing either wild-type (WT) or mutant ERBB2 were
tested for their transforming ability in a soft-agar assay. NMuMg cells infected with empty vector (MiGR1) were used as control. 2.5610
4 cells/well
were plated in a six-well plate and analyzed after 4 weeks. (B) Average number of colonies for each cell line was shown as compared to vector
transfected NMuMg cells.
doi:10.1371/journal.pone.0026760.g003
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Structural modeling was performed to elucidate the possible
mechanisms for lapatinib resistance due to ERBB2 kinase domain
mutations. To date, the crystal structure of ERBB2 has not been
solved. However, the high degree of identity and large number of
crystal structures available for EGFR makes it well suited to also
model structures for the ERBB2 kinase; their ligand binding
surfaces at and near the ATP binding site are almost identical
(Figure S5).
L755S/P. Figure 5A shows contacts between L755 and helix
C that are seen in the active EGFR structures (1M17, 2ITY,
2ITO, 2ITZ, 2ITT, 2TIP). Their geometries are not identical,
with three structures showing a significantly displaced position
(2ITP, 2ITY, 2ITT) that does not however eliminate the contacts;
one of these (2ITY) also shows an additional contact to a displaced
aromatic side chain from the glycine loop hairpin aromat F723
(EGFR numbering). While mutations at L755 will not affect
inhibitor binding directly, they do affect the packing interactions
with helix C, and thus will influence the structure of the active
state and the transition between active and inactive forms. In the
active form (Figure 5A), L755 packs against the helix with
hydrophobic interactions. In inactive forms (Figure 5B), the C-
helix is translated away from the active site, the activation loop
may adopt a helical turn, and L755 does not make ordered contact
with helix C. The activating nature of L755S and L755P
mutations is evident from their ability to transform Ba/F3 cells
to cytokine independence relatively quickly compared to the wild
type ERBB2 kinase in a competition assay (Figure 6B). Moreover,
mutations ERBB2-L755S, ERBB2-L755P and ERBB2-T798M
showed enhanced MAPK signaling compared to both the wild
type and lapatinib-sensitive ERBB2 mutants (Figure 6A). Because
the mutations are transforming, the L755S/P mutations either
stabilize the active state relative to the inactive state or lower a
barrier to activation. L755P may do this by reducing disorder of
Figure 4. Analysis of ERBB2 kinase domain mutants identifies lapatinib-resistant mutations. Ba/F3 cells stably expressing either wild type
or mutant ERBB2 were treated with indicated concentrations of either lapatinib (A) or AEE 788 (B) for 48 hours and analyzed for cell proliferation
inhibition.
doi:10.1371/journal.pone.0026760.g004
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conformation. L755S likely destabilizes the interactions in the
inactive state, observed to be hydrophobic. It is also possible that
L755S introduces stabilizing polar interactions of a structurally
altered active form. In conclusion, mutations affecting L755 seems
to stabilize the active conformation of the ERBB2 kinase. This
would explain the resistance to lapatinib that targets the inactive
conformation of the ERBB2 kinase and the partly retained
sensitivity to AEE778 that target preferentially the active
conformation[14].
T798M. Threonine 798 is the ERBB2 ‘‘gatekeeper’’, the
ATP site residue long known as a primary selectivity determinant
among protein kinases. The gatekeeper is also known as the most
prominent site of drug resistant mutations of Abl kinase against
imatinib and other CML drugs. In these cases, the mutation is T-
.I, which is transforming of itself and also lowers drug binding
strengths[15]. The mutation of the gatekeeper threonine to
methionine is the principle mechanism for drug resistance in
EGFR kinase (T790M). It is known to enhance the affinity of
oncogenic forms of EGFR kinase to ATP[16], explaining its drug
resistant properties despite retention of the ability to bind EGFR
inhibitors. In line with this assumption ERBB2-T798M displays
increased transforming potential compared to wild type ERBB2
(Figure 6B). Figure 5C shows how the binding mode of AEE788
remains unaffected by the ERBB2-T798M mutation. Thus, the
increased affinity of ERBB2-T798M towards ATP might explain
the observed inhibitor resistance towards the reversible inhibitor
AEE788. Figure 5D shows different binding modes for lapatinib
in EGFR kinase and ERBB4, which share high identity with
ERBB2. The binding mode as modelled in EGFR kinase is not
compatible with the T798 mutation, although the binding mode
seen in ERBB4 may be so. Moreover, unlike AEE788, lapatinib
binds the inactive conformation preferentially. Thus, the
stabilization of an active conformation in ERBB2-T798M in
combination with increased affinity to ATP might contribute to
lapatinib resistance.
Irreversible inhibitors potently inhibits drug resistant
ERBB2 mutants
CL-387785 is an irreversible EGFR/ERBB2 inhibitor that was
shown to overcome gefitinib resistance due to the EGFR-T790M
gatekeeper mutation[17]. WZ-4002 was recently reported to have
Figure 5. Structural analysis of lapatinib resistant ERBB2 kinase domain mutants. (A) L755 packs against helix C, closest to residues Ala763
and Ile767, and makes no contacts with the inhibitors (structure 1M17 with inhibitor erlotinib is depicted lower left). (B) Comparing the active
structure of 1M17 (green) to an inactive representative 1XKK bound to lapatinib shows the loss of L755 interactions (cyan). (C) Overlay of AEE788
bound structures of EGFR (2J6M, active, blue) and EGFR T790M (2JIU, inactive, yellow). The existence of the salt bridge linking the active site lysine
K753 with the helix C E770 is a marker for the active state. The T798M (ERBB2 numbering) mutation does not significantly alter binding, although a
rotation of the inhibitor aromat is apparent. (D) Superposition of two binding modes of lapatinib onto the overlay of figure 2C and display of the
T798M atoms as Van der Waals spheres shows how the binding mode seen in 1XKK (cyan) obviously clashes with the mutation, but the binding
mode of 3BBT (pale blue, ERBB4, which also has threonine as gatekeeper) does not.
doi:10.1371/journal.pone.0026760.g005
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and mutant EGFR[18,19]. Moreover, irreversible inhibitors were
recently shown to overcome inhibitor resistance caused due to
insertion mutations in the ERBB2 kinase[20–22]. Thus, we tested
the efficacy of these irreversible inhibitors CL-387785 and WZ-
4002 (Figure S3) on lapatinib-resistant ERBB2 point mutations
(L755S, L755P and T798M). Interestingly, both inhibitors
potently inhibited proliferation of Ba/F3-ERBB2 mutant cell
lines with IC50 values less than 200 nM (Figure 7A and 7B).
WZ-4002 was more potent (fold-increase of IC50 of mutant
ERBB2 compared to wild type ERBB2) than CL-387785 (Table
S2). Biochemical analysis of ERBB2 kinase activity and
downstream targets showed that both irreversible inhibitors
showed significant activity towards all three resistant ERBB2
mutants (Figure 7C and 7D). The structural basis for the excellent
activity of WZ-4002 against lapatinib resistant ERBB2 mutations
may be attributed to its ability to bind an active conformation of
the ERBB2 kinase in an irreversible manner. Thus, WZ-4002
Figure 6. Lapatinib-resistant ERBB2 mutants show increased transformation potential of Ba/F3 cells to cytokine independence. (A)
Ba/F3 cells transformed by ERBB2 mutants were analysed by western blotting for the activation of ERBB2 and downstream ERK phosphorylation. (B)
To test the activating nature of lapatinib-resistant mutations, Ba/F3 cells were transduced with wild type or mutant MSCV-eGFP-ERBB2 and
outgrowth of ERBB2-positive (green) cells with respect to parental (non-green) Ba/F3 cells was measured by FACS analysis at indicated time points.
doi:10.1371/journal.pone.0026760.g006
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with either primary or secondary lapatinib resistance due to
ERBB2 kinase domain mutations located at L755 or T798 within
a clinical trial.
In summary, in this study lapatinib-resistant ERBB2 kinase
domain mutations were identified and the efficacy of irreversible
inhibitors to overcome lapatinib resistance is demonstrated.
Moreover, an ERBB2 mutant (H878Y) observed in 11% of
hepatocellular carcinoma patients showed remarkable sensitivity
to lapatinib indicating that lapatinib may be an attractive option in
the future for hepatoma patients with ERBB2-H878Y.
Materials and Methods
Chemical reagents, DNA constructs and cell culture
Erlotinib and lapatinib was purchased from the pharmacy.
Gefitinib was kindly provided by AstraZeneca, and AEE788 was
a kind gift from Novartis Pharma AG, Basel. CL-387785 was
purchased from Calbiochem and WZ-4002 was purchased from
Axon Medchem. Each compound was dissolved in DMSO to
make an initial stock solution of 10 mmol/L (gefitinib, AEE788
and WZ-4002), 2.5 mmol/L (erlotinib and lapatinib) and
1 mmol/L (CL-387785). Human EGF was purchased from
Chemicon and recombinant human Heregulin was purchased
from Calbiochem.
MiGR1-ERBB2 and pcDNA-ERBB3 were a kind gift from
Prof. Dr. Helga Bernhard. Point mutations were introduced in to
MiGR1-ERBB2 as described previously[9,10]. All mutations were
confirmed by sequencing.
Ba/F3 cells were cultured in RPMI 1640 (Life Technologies)
supplemented with 10% FCS, glutamine, and interleukin-3 (IL-3;
R&D Systems). Stable Ba/F3 cell lines expressing wild type or
mutant ERBB2 were established by retroviral infection with
MiGR1-ERBB2 followed by IL-3 withdrawal. HEK293 cells were
cultured in DMEM (Life Technologies) supplemented with 10%
FCS. Murine mammary epithelial cell line NMuMg was cultured
in DMEM supplemented with 10% FCS, NaHCO3 and insulin.
Stable NMuMg cell lines were established by retroviral infection
with either wild type or mutant ERBB2 constructs.
Western blotting, soft agar assay, and cell proliferation
assay
HEK293 cells were transfected with MiGR1-ERBB2 constructs
either alone or in combination with EGFR/ERBB3 cDNA for
36 hours before serum starvation for 12 hours. Cells were then
Figure 7. Irreversible inhibitors overcome lapatinib resistance due to ERBB2 kinase domain mutations. Stable Ba/F3 cell lines
expressing either wild type or mutant ERBB2 were treated with indicated concentrations of either CL-387785 (A) or WZ-4002 (B) for 48 hours and
analyzed for inhibibtion of cell proliferation. Indicated Ba/F3-ERBB2 cell lines were treated with increasing concentrations (50 nM, 100 nM, 250 nM,
500 nM or 1000 nM) of either CL-387785 (C) or WZ-4002 (D) for 30 minutes and analyzed by western blotting with indicated antibodies.
doi:10.1371/journal.pone.0026760.g007
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50 ng/ml of heregulin (Calbiochem) for 5 minutes and pelleted for
cell lysis. Ba/F3 cells[9] expressing either wild type or mutant
ERBB2 constructs were treated with either CL-387785 or WZ-
4002 for 30 minutes and pelleted. Cell lysis, SDS-PAGE and
Western blotting were done as described previously[9,10]. The
following antibodies were used: phosphorylated ERBB2-Tyr
1248
(Millipore), ERBB2-Tyr
1221/1222 (Santa Cruz Biotechnology),
ERBB2 (Santa Cruz Biotechnology), p44/42 mitogen-activated
protein kinase [extracellular signal-regulated kinase (ERK1/
ERK2)] (Cell Signaling), phosphospecific ERK1/ERK2 (Cell
Signaling), pStat5-Tyr
694 (Cell Signaling), Stat5 (Santa Cruz
Biotechnology), p-SAPK/JNK (Thr183/Tyr185) (Cell Signaling),
SAPK/JNK (Cell Signaling), pAKT (Ser473) (Cell Signaling), and
AKT1/2 (Santa Cruz Biotechnology). Bands were visualized using
the enhanced chemiluminescence system (Amersham).
Anchorage-independent cell growth was analysed by colony
formation ability in soft agar assay as described previously[19].
Analysis of cell proliferation was done using an 3-(4,5-dimethylthia-
zol-2-yl)-5-[3-carboxymethoxyphenyl-2-(4-sulfophenyl)-2H-tetrazo-
lium (MTS)]-based method by absorption of formazan at 490 nm
(CellTiter 96; Promega). Samples were measured in triplicates after
48 h of culture in indicated drug concentrations.
Lapatinib resistance screen
Ba/F3 cells stably expressing wild type ErbB2 were treated
twice with 100 mg/mL of N-ethyl-N-nitrosourea (ENU) for
12 hours. Cells were then washed thoroughly and cultured in
96-well plates at a density of 4610
5 per well in the presence of
2 mM lapatinib. Lapatinib resistant cell colonies were isolated.
Total RNA was extracted using TRIzol reagent (Invitrogen).
cDNA encompassing ErbB2 kinase domain was synthesized by
one step reverse-transcription PCR (Promega) and sequenced.
Structural analysis of lapatinib resistant ERBB2 mutants
Crystal structure coordinates for inhibitor complexes with the
ErbB1 kinase domain (ErbB1-KD), ErbB1-KD mutations, and
ErbB4-KD are available from the Protein Data Bank (www.pdb.
org).Crystalstructuresofcomplexeswitherlotinib(1M17),lapatinib
(1XKK,3BBT),gefitinib (2ITY, 2ITO,2ITZ),and AEE788 (2J6M,
2ITP, 2ITT, 2JIU), representing both active and inactive states of
the kinase domain, were superimposed and inspected using the
graphics program PyMOL (www.pymol.org)[14,16,23–25].
Supporting Information
Figure S1 Colony formation by early-passage NMuMg
cells stably expressing ERBB2 mutants. 2.5610
4 cells per
well were plated in a six-well plate and analyzed for colony
formation. NMuMg cell line infected with MiGR1 vector is used
as a control.
(TIF)
Figure S2 Colony formation by late-passage NMuMg
cells. Late-passage NMuMg cells stably expressing ERBB2
mutants were analyzed for colony formation. Cells infected with
MiGR1 vector is shown as control.
(TIF)
Figure S3 Structures of reversible (A) and irreversible
(B) inhibitors used in this study.
(TIF)
Figure S4 Cell-based screen for lapatinib resistance.
Schematic representation of lapatinb resistance screen performed
with Ba/F3 cells stably expressing wild type ERBB2 kinase (A).
Residues affected by lapatinib resistance mutations identified in
the in vitro screen were conserved in other ERBB members except
ERBB3 (B).
(TIF)
Figure S5 Surface representation of EGFR kinase.
Surface representation of EGFR (in complex with erlotinib,
1M17), showing potential binding surfaces attributable to residues
that differ between EGFR and ERBB2. Only one site is within the
ATP binding pocket (Cys775-.Ser). A second is close by; Phe795
in EGFR is replaced by Tyr803 in ErbB2 visible near an ether
chain of the inhibitor to the left of the binding cleft.
(TIF)
Table S1 Representation of previously reported EGFR
mutations homologous to ERBB2 mutants that were
analyzed in this study.
(TIF)
Table S2 Summary of relative resistance profiles of
ERBB2 mutants against AEE 788, CL-387785 and WZ-
4002 compared to lapatinib. Approximate fold-increase in
IC50 value of indicated ERBB2 mutant compared to wild type
ERBB2 are calculated and classified as less (green), moderate
(yellow) or highly (red) resistant.
(TIF)
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